OTHER
Therapeutics
Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes
| The first 150 words of the full text of this article appear below. |
randomised placebo-controlled trial (Hyperinsulinemia: the Outcome of its Metabolic Effects [HOME]). ClinicalTrials.gov NCT00375388 [ClinicalTrials.gov] .
{concealed}*.
blinded (patients, clinicians, {data collectors, outcome assessors, data analysts, safety committee, and writers}*).
outpatient clinics of 3 hospitals in Hoogeveen, Meppel, and Coevorden, the Netherlands.
390 patients 30–80 years of age (mean age 61 y, 54% women) who had type 2 diabetes.
metformin hydrochloride, 850 mg 1–3 times daily (n = 196), or matching placebo (n = 194), with insulin therapy.
composite of microvascular and macrovascular disease (myocardial infarction [MI]; heart failure; acute coronary syndrome; peripheral arterial disease; sudden death; progression of retinopathy, nephropathy, or neuropathy; and 9 other items). Secondary outcomes included microvascular disease, macrovascular disease, and metabolic end points (body weight, blood pressure [BP], insulin dose, haemoglobin [Hb] A1c, and lipid concentrations). The study had 75% power to detect a
8% difference between groups in the primary composite end point at
Scott and White Clinic, Texas A & M Health Sciences Center; Temple, Texas, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
